Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, July 11, 2022 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces that 167,394 warrants held by employees under the 2019 Warrant Program ("TO2") have been fully exercised, providing ExpreS2ion SEK 805,165. The exercise has increased the number of shares by 167,394 from 36,994,712 to 37,162,106.
At an Extra General Meeting in ExpreS[2]ion held on May 23, 2019, it was resolved to issue warrants as part of an incentive program for employees ("the 2019 Warrant Program", or "TO2"). The program comprised a total of 680,100 warrants, where one (1) warrant entitled to subscription of one (1) share in the Company. 612,084 were subscribed for and allocated to the employees. The warrants stipulated a subscription price of SEK 4.81 per share. The TO2 exercise period is in three months from June 1 through August 31 and is carried out in three tranches during the respective months. The 167,394 warrants cover the first of the three tranches.
Number of shares, share capital and dilution
The new shares in the first tranche have now been registered by the Swedish Companies Registration Office (Sw. Bolagsverket). The number of shares in ExpreS[2]ion has increased by 167,394, from 36,994,712 to 37,162,106 shares. The total share capital amounts to SEK 4,129,122.90. The dilution effect for the company's existing shareholders amounted to approximately 0.45 percent.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se